Perioperative Chemo and Pembrolizumab in Gastric Cancer
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, multi-site, open-label trial of pembrolizumab and chemotherapy in
subjects with gastric or gastroesophageal (GE) junction adenocarcinoma. The purpose of this
study is to determine and evaluate the efficacy of combination therapy with immune checkpoint
blockade and chemotherapy used in the perioperative period in eradicating micrometastatic
disease; and to compare paired tissue and serum samples (pre-treatment and post-treatment)
from individually treated patients to explore the immune effects of combination therapy and
predictors of response.